Distinct batches of MβCD produced by different commercial laboratories may be more or less effective in reducing the cholesterol that accumulates in the fibroblasts of patients with the lysosomal storage disorder Niemann-Pick disease type C1.
‘Methyl-β-Cyclodextrin (MβCD) reduces lysosomal cholesterol accumulation in Niemann-Pick Disease (lysosomal storage disorder). Quality control method for pharmacological activity of Methyl-β-Cyclodextrin (MβCD) may help in better treatment outcomes.’
This new set of methods for selecting an optimal cyclodextrin preparation is described in
ASSAY and Drug Development Technologies, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the ASSAY and Drug Development Technologies website.
Wei Zheng, PhD, National Center for Advancing Translational Sciences, National Institutes of Health (Bethesda, MD) and coauthors from the NIH, Poochon Scientific (Frederick, MD), and Washington University School of Medicine (St. Louis, MO), developed an analytical method that they used to characterize three preparations of MβCD.
The researchers found differences in average molecular weight and side chain methylation in MβCD samples from different vendors and batches.
They discuss the potential impact of these differences on the ability of MβCD to reduce lysosomal cholesterol accumulation in the article entitled "Analytical Characterization of Methyl-β-Cyclodextrin for Pharmacological Activity to Reduce Lysosomal Cholesterol Accumulation in Niemann-Pick Disease Type C1 Cells."
"This scientific disclosure highlights the importance of consistency in batch production of MβCD. Without this technology, there would be little promise to develop a clinical treatment for these patients, many of whom are young children," says ASSAY and Drug Development Technologies Editor-in-Chief Bruce Melancon, PhD, Managing Director of the Chemical Synthesis and Drug Discovery facility at the University of Notre Dame.
Source: Eurekalert
Careers
